IC
Immuno Cancer Biotherapeutics, Inc.
StreetZero Signal 65
About Immuno Cancer Biotherapeutics, Inc.
Immuno Cancer Biotherapeutics, Inc. raised $75K in a Private Placement round, based in CANTON, SD. Company intelligence is being researched.
LATEST FUNDINGPrivate Placement
$75K
Announced 2026-10-15
IN THE NEWS
- 🔗 Immune-Onc Therapeutics Announces $73 Million in Series B1 and B2 Financing to Advance its Portfolio of Novel Immunotherapies in Blood Cancers and Solid Tumors — Immune-Onc Therapeutics
- 🔗 Immunomic Therapeutics Announces Close of $61.3M Financing - Immunomic Therapeutics
- 🔗 List of Immuno-Oncology Companies with Phase 2 Active Clinical Trial
- 🔗 Bolt Biotherapeutics to Present Updates on Three Pipeline Programs at the 2021 Society for Immunotherapy of Cancer Annual Meeting (SITC)
- 🔗 ImmunOs Therapeutics AG raises CHF 15M in Series A Financing, co-led by Pfizer Ventures and BioMedPartners, to Advance a Novel Immunotherapy Agent For Cancer Into Human Trials | Pfizer
EMPLOYEES—
FOUNDED—
HQCANTON, SD
Industry
Biotechnology
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Ask StreetZero about Immuno Cancer Biotherapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account